血管紧张素转化酶抑制剂治疗肝纤维化的研究进展  

Research progress on angiotensin converting enzymeinhibitors in treating liver fibrosis

作　　者：陈云梅 王娜娜[1,2] 张怡心 谭雄 秦蓓 CHEN Yunmei;WANG Nana;ZHANG Yixin;TAN Xiong;QIN Bei(School of Pharmacy,Xi’an Medical University,Xi’an 710021,China;Xi’an Key Laboratory of Innovative Drugs Development for Multi-target Synergistic Antihypertensive Treatment,Xi’an 710021,China;School of Pharmacy,Chengdu Medical College,Chengdu 610500,China)

机构地区：[1]西安医学院药学院,陕西西安710021 [2]西安市多靶协同抗高血压创新药物研制重点实验室,陕西西安710021 [3]成都医学院药学院,四川成都610500

出　　处：《化工科技》2024年第3期70-76,共7页Science & Technology in Chemical Industry

基　　金：陕西省科技厅自然科学基础研究计划(2024JC-YBQN-0956);陕西省教育厅科研计划项目(23JK0651);陕西省重点研发计划项目(2021ZDLSF03-05);西安医学院博士科研启动金(2021DOC17);西安医学院校级科技创新团队(2021TD03);陕西省大学生创新创业训练计划项目(S202211840064)。

摘　　要：肝纤维化是各种慢性肝病向肝硬化发展的重要环节。临床研究实验表明,血管紧张素转换酶抑制剂(Angiotensin Converting Enzyme Inhibitors,ACEI)具有良好的抗纤维化效果。本文主要从肾素-血管紧张素系统、肝细胞凋亡、肝星状细胞激活、细胞外基质降解、氧化应激以及相关信号通路等肝纤维化发生机制简要介绍ACEI如何影响肝纤维化的进程,以期为肝纤维化的治疗提供新思路。Liver fibrosis is the inevitable stage of cirrhosis of liver.It has been proved that angiotensin converting enzyme inhibitors(ACEI)is effective on the treatment of liver fibrosis in animal experiment and clinical trials.This review briefly summarizes how ACEI affect the progression of liver fibrosis based on the molecular mechanisms underlying the progression of liver fibrosis,including renin-angiotensin system,hepatic stellate cells activation,extracellular matrix degradation,oxidative stress and relative signaling pathway.We wish this review could provide novel ideas and means for the prevention and treatment of liver fibrosis.

关 键 词：血管紧张素转化酶抑制剂 肝纤维化 发生机制 血管紧张素Ⅱ 

分 类 号：R282[医药卫生—中药学]